Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVC-422 for Bacteriuria in Chronically Catheterized Subjects
NCT00781339Phase 2Completed
- Sponsor
- NovaBay Pharmaceuticals, Inc.
- Start
- Oct 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of auriclosene in asymptomatic bacteriuria (ASB), sponsored by NovaBay Pharmaceuticals, Inc. Primary endpoint: Safety and antimicrobial effect of NVC-422 in urine. Started Oct 2008; status: completed.
02
Drugs
auriclosene
03
Conditions
asymptomatic bacteriuria (ASB)
Beyond the preview
Go deeper on NCT00781339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00781339.